about
ING proteins as potential anticancer drug targets.A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumorsInhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.Ligand-directed profiling: applications to target drug discovery in cancer.FoxM1 is a downstream target and marker of HER2 overexpression in breast cancerA framework for genomic biomarker actionability and its use in clinical decision makingQuantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variablesHeregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.Epidermal growth factor receptor signaling in nonsmall cell lung cancer.Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
P2860
Q33574029-B89D2051-7604-4626-B8BD-57B9CBA599BBQ33619858-7F7B152A-3337-4070-8845-79E95145AC32Q33920097-612905AB-E25B-4EC1-BD54-83F03DA5A727Q33939820-32AFEE6D-1640-4EB1-953C-1881BE48A611Q34616650-F4EB6AA8-3EF5-436C-8F05-A45EB42F2C48Q34725700-1C8919EF-82E9-4F09-8C7F-D586DC201C7DQ34781122-42F4CBBC-A24E-4178-BD6C-4F22F891390BQ35131931-F90A8340-739A-4220-80E9-FA7E99654ECEQ36393289-8A7D65D5-560E-4990-ACFB-658F0619F423Q36481002-71D4B6DF-3254-48BE-9E2E-5BD7AD7F414FQ36608839-743D6839-DB3C-459C-838D-CC3F1C69D72CQ39752055-CBA4EFAC-2571-4A07-829B-C82DDD2E35D0Q42745155-EB5B7C11-5D10-4089-9D60-56B8E643D041Q45065769-AB20452D-5B27-4CFC-B883-7AD3E5E20681Q46351405-9B1C2C9D-13EF-4D43-97AD-343F192F1C2FQ47611571-603AB9C2-8B08-411E-B434-AEE91889A274Q53693680-93C27915-DBE8-441A-BD76-6719CE1612CD
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clinical experience with gefitinib: an update.
@ast
Clinical experience with gefitinib: an update.
@en
type
label
Clinical experience with gefitinib: an update.
@ast
Clinical experience with gefitinib: an update.
@en
prefLabel
Clinical experience with gefitinib: an update.
@ast
Clinical experience with gefitinib: an update.
@en
P2093
P50
P1476
Clinical experience with gefitinib: an update.
@en
P2093
Alessandra Cancellieri
Elisabetta Magrini
Giovanna Finocchiaro
Giulio Metro
Luciano Castaldini
Lucio Crino
Stefania Bartolini
P356
10.1016/J.CRITREVONC.2005.08.008
P577
2006-03-13T00:00:00Z